期刊文献+

钙泊三醇倍他米松软膏联合卡泊三醇软膏序贯治疗寻常型银屑病疗效评价 被引量:19

Efficacy of calcipotriol betamethasone ointment combined with calcipotriene ointment on psoriasis vulgaris
下载PDF
导出
摘要 目的:评价钙泊三醇倍他米松软膏联合卡泊三醇软膏治疗寻常型银屑病的临床疗效。方法:30例银屑病患者全身左右侧皮损随机分为治疗组或对照组。治疗组外用钙泊三醇倍他米松软膏和卡泊三醇软膏;对照组外用卡泊三醇软膏。治疗第2、4、8周末进行疗效评价。结果:治疗2、4、8周后治疗组有效率(53.33%、70%和86.67%)均明显高于对照组(30%、46.67%和66.67%),组间差异均有统计学意义(P<0.05)。结论:钙泊三醇倍他米松软膏联合卡泊三醇软膏治疗寻常型银屑病疗效较单独使用卡泊三醇好。 Objective:To assess the efficacy of calcipotriol betamethasone ointment combined with calcipotriene ointment in the treatment of psoriasis vulgaris.Methods:One side of body of 30 patients was treatedwith calcipotriol betamethasone ointment combined with calcipotriene ointment(treatment group) and the otherside was treated with calcipotriene ointment(control group).The efficacy was assessed at week 2,4 and 8 after treatment.Results:The effective rates in the treatment group at week 2,4 and 8 after treatment were53.33%,70% and 86.67%,which was higher than those in the control group(30%,46.67% and 6.67%,respectively),with significant differences(P〈0.05).Conclusion:Calcipotriol betamethasone ointment combined with calcipotriene ointment is more effective than calcipotriene ointment alone in the treatment of psoriasis vulgaris.
出处 《中国麻风皮肤病杂志》 2016年第6期369-370,共2页 China Journal of Leprosy and Skin Diseases
关键词 银屑病 钙泊三醇倍他米松 卡泊三醇 psoriasis calcipotriol betamethasone calcipotriene
  • 相关文献

参考文献6

二级参考文献48

  • 1Marks R, Barton SP, shuttleworth D, et al. Assessment of disease in psoriasis. Arch Dermafol 1989; 125(2) :235 - 240.
  • 2马振友.国家基本药物与新特药手册.皮肤科.西安:世界图书出版西安公司,2002.315.
  • 3Kimball AB, Jacobson C, Weiss S, et al. The psychosocial bur- den of psoriasis[J]. Am J Clin Dermatol, 2005, 6(6): 383-392.
  • 4van de Kerkhof PC, Wasel N, Kragballe K, et al. A two-com- pound product containing calcipotriol and betamethasone dipropi- onate provides rapid, effective treatment of psoriasis vulgaris re- gardless of baseline disease severity[J]. Dermatology, 2005, 210 (4): 294-299.
  • 5Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipro- pionate ointment[J]. Int J Dermatol, 2006, 45(8): 970-975.
  • 6Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotri- ol/betamethasone dipropionate two-compound product (Daivobet/ Dovobet/Taclonex) in the treatment of psoriasis vulgaris[J]. Der- matology, 2006, 213(4): 319-326.
  • 7Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis[J]. J Eur Acad Dermatol Venereol, 2006, 20(1): 39-44.
  • 8Thaci D, Ortonne JP, Chimenti S, et al. A phase rob, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/ betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study [ J ]. Br J Dermatol, 2010, 163(2): 402-411.
  • 9Sticherling M, Eicke C, Anger T. Practicability of combined treatment with calciporticol/betamethasone gel and improvement of quality of life in patients with psoriasis [ J ]. J Dtsch Dermatol Ges, 2013, 11(5): 420-427.
  • 10Fe|dman SR. A quantitative definition of severe psoriasis for use in clinical trials[J]. J Dermatol Treat, 2004, 15( 1 ): 27-29.

共引文献30

同被引文献111

引证文献19

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部